Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Exploratory results from the OMEGA Phase 1 trial demonstrated that OMIT with INT301 produced a ≥50-fold increase in peanut tolerance threshold in adults.
-
Intrommune welcomes an independent editorial that was recently published in Annals of Allergy, Asthma & Immunology.
-
Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
-
New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy
-
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy
-
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy
-
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
-
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...
-
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...
-
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...